Epigenetic Modulation of Collagen 1A1: Therapeutic Implications in Fibrosis and Endometriosis

Area of Science:

• Epigenetics
• Molecular Biology
• Fibrosis Research

Background:

• Progressive fibrosis complicates chronic diseases and surgical healing, often resisting conventional treatments.
• Endometriosis, characterized by uterine tissue implantation and scarring, presents a significant fibrotic challenge.
• The transcription factor KLF11 is found to be diminished in endometriosis lesions, correlating with increased fibrosis.

Purpose of the Study:

• To investigate a novel mechanism regulating scar-tissue collagen (COL1A1/Col1a1) expression.
• To assess the translational relevance of this mechanism as a targeted therapy for fibrosis.
• To evaluate the role of KLF11 in regulating COL1A1/Col1a1 expression and its impact on fibrosis in an endometriosis model.

Main Methods:

• Modulation of COL1A1/Col1a1 expression in human endometrial-stromal fibroblasts.
• Investigating the recruitment of SIN3A/HDAC by KLF11 and its effect on COL1A1 promoter deacetylation.
• Utilizing histone acetyl transferase (garcinol) and HDAC (suberoyl anilide hydroxamic acid) inhibitors in KLF11 knockout and wild-type animal models.

Main Results:

• Loss of KLF11-mediated repression led to increased COL1A1/Col1a1 expression and fibrosis.
• KLF11 recruits SIN3A/HDAC to deacetylate and repress the COL1A1 promoter.
• Pharmacological inhibition of histone acetyl transferase reversed fibrosis in KLF11 deficient models, while HDAC inhibition reversed fibrosis in wild-type models.
• Fibrosis reversal was dependent on lesion genotype, not host genotype.

Conclusions:

• This study demonstrates a novel epigenetic mechanism regulating fibrosis via KLF11 and COL1A1/Col1a1.
• Targeted pharmacological reversal of fibrosis is feasible, offering a potential therapeutic strategy for intractable fibrotic conditions.
• The findings highlight the potential of epigenetic modifiers for treating fibrosis in diseases like endometriosis.